Novel approaches including gene editing are creeping towards approval.
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
ALXN1840 could challenge older copper chelators, but gene therapies are coming.
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.